Acute kidney injury in patients with human immunodeficiency virus infection

Current Opinion in Critical Care

Volumn 14, Issue 6, 2008, Pages 647-653

  Cohen, Scott D ^a   Chawla, Lakhmir S ^a   Kimmel, Paul L ^a,b  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute kidney injury; Epidemiology; Human immunodeficiency virus

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CIDOFOVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; FOSCARNET; GANCICLOVIR; HISTAMINE H2 RECEPTOR ANTAGONIST; INDINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; PHENYTOIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONAMIDE; TENOFOVIR; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; CD4 LYMPHOCYTE COUNT; CRYSTALLURIA; CYSTITIS; DIABETES INSIPIDUS; DIFFERENTIAL DIAGNOSIS; FANCONI RENOTUBULAR SYNDROME; GLOMERULONEPHRITIS; GLUCOSURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; HYPOURICEMIA; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY INJURY; NEPHROLITHIASIS; NEPHROTOXICITY; OBSTRUCTIVE UROPATHY; PLASMAPHERESIS; PNEUMOCYSTOSIS; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; THROMBOCYTOPENIC PURPURA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA;

ACUTE DISEASE; AIDS-ASSOCIATED NEPHROPATHY; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; KIDNEY DISEASES; MALE; RISK FACTORS; SEX FACTORS; UNITED STATES;

EID: 57149117843     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3283186f43     Document Type: Review

References (99)

1. Rao TKS, Friedman EA. Outcome of severe acute renal failure in patients with acquired immunodeficiency syndrome. Am J Kidney Dis 1995; 25:390-398.
2. Rao TKS. Acute renal syndromes in human immunodeficiency virus infection. Semin Nephrol 1998; 18:378-395.
3. Rao TKS. Renal complications in HIV disease. Med Clin North Am 1996; 80:1437-1451.
4. Wyatt CM, Arons RR, Klotman PE, Klotman ME. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 20:561-565.
5. Izzedine H, Baumelou A, Deray G. Acute renal failure in HIV patients. Nephrol Dial Transplant 2007; 22:2757-2762. A critical review of acute renal failure in HIV infected patients that focuses on the epidemiology of this disease and the mechanisms underlying HAART related nephropathy.
6. D'Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol 1997; 8:138-152.
7. Weiner NJ, Goodman JW, Kimmel PL. The HIV-associated renal diseases: current insight into pathogenesis and treatment. Kidney Int 2003; 63:1618-1631.
8. Kimmel PL, Barisoni L, Kopp JB. Pathogenesis and treatment of HIV-associated renal diseases: lessons from clinical and animal studies, molecular pathologic correlations, and genetic investigations. Ann Intern Med 2003; 139:214-226.
9. Franceschini N, Napravik S, Eron JJ Jr, et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int 2005; 67:1526-1531.
10. Naicker S, Aboud O, Gharbi MB. Epidemiology of acute kidney injury in Africa. Semin Nephrol 2008; 28:348-353. An analysis that focuses on the diverse etiologies of acute renal failure in South Africa including patients infected with HIV.
11. Lopes JA, Fernandes J, Jorge S, et al. An assessment of the RIFLE criteria for acute renal failure in critically ill HIV-infected patients. Crit Care 2007; 11:401.
12. Roe J, Campbell LJ, Ibrahim F, et al. HIV care and the incidence of acute renal failure. Clin Infect Dis 2008; 47:242-249. A recent observational study from the United Kingdom that focuses on the epidemiology of AKI in the setting of HIV infection and supports earlier studies by Wyatt et al. and Franceschini et al. regarding risk factors for the development of AKI.
13. Valeri A, Neusy AJ. Acute and chronic renal disease in hospitalized AIDS patients. Clin Nephrol 1991; 35:110-118.
14. Perazella MA. Acute renal failure in HIV-infected patients: a brief review of common causes. Am J Med Sci 2000; 319:385-391.
15. Moriyama Y, Minamidate Y, Yasuda M, et al. Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient. Urol Res 2008; 36:275-277.
16. Kennedy WA II, Benson MC, Kaplan SA. Urologic manifestations of HIV infection. In: Kimmel PL, Berns JS, J Stein, editors. Renal and urologic complications of HIV infection. Contemporary issues in nephrology. New York, NY: Churchill Livingstone; 1995. pp. 181-193.
17. Comiter S, Classer J, Al-Askavies S. Ureteral obstruction in a patient with Burkitt's lymphoma. Urology 1992; 39:277-280.
18. Ogea Garcia JL, Villanueava Marcos JL, Jurado R, et al. Burkitt's lymphoma and AIDS. Their presentation as tumoral hepatomegaly and acute renal failure due to tubular deposits of urates. Ann Med Intern 1989; 6:551-552.
19. Cohen SD, Chawla LS, Kimmel PL. Human immunodeficiency virus and acute kidney failure. 2nd ed. In: Ronco C, Bellomo R, Kellum JA, editors. Critical care nephrology. Philadelphia: Saunders/Elsevier; (in press).
20. Barraclough K, Harris M, Montessori V, Levin A. An unusual case of acute kidney injury due to vancomycin lessons learnt from reliance on eGFR. Nephrol Dial Transplant 2007; 22:2391-2394.
21. Pannu N, Wiebe NM, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006; 295:2765-2779.
22. Roling J, Schmid H, Fischereder M, et al. HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy. Clin Infect Dis 2006; 42:1488-1495.
23. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
24. Gagnon RF, Tecimer SN, Watters AK, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis 2000; 36:507-515.
25. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127:119-125.
26. Voigt E, Wickesberg A, Wasmuth JC, et al. First-line ritonavir/indinavir 100/ 800mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicenter study: 48-week results. HIV Med 2002; 3:277-282.
27. Dieleman JP, Gyssens IC, Van Der Ende ME, et al. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS 1999; 13:473-478.
28. Boubaker K, Sudre P, Bally F, et al. Changes in renal function associated with indinavir. AIDS 1998; 12:F249-F254.
29. Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol 2000; 54:261-270.
30. Daugas E, Rougier JP, Hill G. HAART-related nephropathies in HIV-infected patients. Kidney Int 2005; 67:393-403.
31. Goicoechea M, Best B. Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? Expert Opin Pharmacother 2007; 8:371-382.
32. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002; 40:1331-1333.
33. Perazella M. Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity. Am J Med Sci 2003; 325:349-362.
34. Coca S, Perazella MA. Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. Am J Med Sci 2002; 324:342-344.
35. Creput C, Gonzalez-Canali G, Hill G, et al. Renal lesions in HIV-1-positive patient treated with tenofovir. AIDS 2003; 17:935-937.
36. Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicty in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi's syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36:1070-1073.
37. Izzedine H, Hulot JS, Vittecoq D, et al. Long term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1 -infected patients. Data from a double-blind randomized active-controlled multicenter study. Nephrol Dial Transplant 2005; 20:743-746.
38. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis 2005; 45:804-817.
39. Izzedine H, Isnard-Bagnis C, Hulot JS, et al. Renal safety of tenofovir in HIV treatment-experienced patients. AIDS 2004; 18:1074-1076.
40. Reid G, Wielinga P, Zelcer N, et al. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 2003; 63:1094-1103.
41. Izzedine H, Launay-Vacher V, Deray G, et al. Renal tubular transporters and antiviral drugs: an update. AIDS 2005; 19:455-462,
42. Goicoechea M, Liu S, Best B, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 2008; 197:102-108. A recent study that shows that HIV-infected patients on a regimen of tenofovir + protease inhibitor had a greater decline in renal function compared with patients taking tenofovir + NNRTI. This clinical trial provides support for a postulated mechanism underlying tenofovir induced proximal tubulopathy.
43. Buchacz K, Young B, Baker RK, et al. The HIV outpatient study (HOPS) investigators. Renal function in patients receiving tenofovir with ritonavir/ lopinavir or ritonavir/atazanavir in the HIV outpatient study (HOPS) cohort. J Acquir Immune Defic Syndr 2006; 43:626-628.
44. Olyaei AJ, deMattos AM, Bennett WM. Renal toxicity of protease inhibitors. Curr Opin Nephrol Hypertens 2000; 9:474-476.
45. Duong M, Sgro C, Grappin M, et al. Renal failure after treatment with ritonavir. Lancet 1996; 348:693.
46. Stricker RB, Man KM, Bouvier DB, et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 1997; 349:1745-1746.
47. Witzke O, Plentz A, Schafers RF, et al. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS 1997; 11:836-838.
48. Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Mod 1997; 336:138.
49. Bochet MW, Jacquiaud C, Valentin MA, et al. Renal insufficiency induced by ritonavir in HIV-infected patients. Am J Med 1998; 105:457.
50. Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS 2005; 19:844-845.
51. Crum-Cianflone N, Quigley M, Utz G, Hale B. BK virus-associated renal failure among HIV patients. AIDS 2007; 21:1501-1502.
52. Zafrani L, Coppo P, Dettwiler S, et al.. Nephropathy associated with the diffuse infiltrative lymphocytosis syndrome. Kidney Int 2007; 72:219-224. This case report describes an HIV-infected patient who developed acute interstitial nephritis in the setting of DILS. There have been increasing reports of tubulointerstitial nephritis leading to AKI in the setting of DILS and therefore this syndrome should be added to the spectrum of etiologies of AKI in HIV-infected patients.
53. Izzedine H, Brocheriou I, Valentin MA, et al. A case of acute renal failure associated with diffuse infiltrative lymphocytosis syndrome. Nat Clin Pract Nephrol 2008; 4:110-114. Another recent case report describing AIN in the setting of DILS.
54. Daugas E, Plaisier E, Boffa JJ, et al. Acute renal failure associated with immune restoration inflammatory syndrome. Nat Clin Pract Nephrol 2006; 2:594-598.
55. Salliot C, Guichard I, Daugas E, et al. Acute kidney disease due to immune reconstitution inflammatory syndrome in an HIV-infected patient with tuberculosis. J Int Assoc Physicians AIDS Care 2008; 7:178-181.
56. Chariot P, Ruet E, Authier FJ, et al. Acute rhabdomyolysis in patients infected by human immunodeficiency virus. Neurology 1994; 44:1692-1696.
57. Joshi MK, Liu HH. Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care and STDs 2000; 14:541-548.
58. Delo D, Brett AS, Postic B. Primary HIV infection presenting with acute rhabdomyolysis. Am J Med Sci 2006; 332:46-47.
59. Peraldi MN, Maslo C, Akposso K, et al. Acute renal failure in the course of HIV infection: a single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol Dial Transplant 1999; 14:1578-1585.
60. Walker S, Norwood J, Thorton C, Schaberg D. Trimethoprim/sulfamethoxazole rhabdomyolysis in a patient with AIDS: case report and review of the literature. Am J Med Sci 2006; 331:339-341.
61. Illa I, Nath A, Dalaakas M. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann Neurol 1991; 29:474-481.
62. Chad DA, Smith TW, Blumenfeld A, et al. Human immunodeficiency virus (HIV)-associated myopathy: immunocytochemical identification of an HIV antigen (gp 41) in muscle macrophages. Ann Neurol 1990; 28:579-582.
63. Mhiri C, Baudnmont M, Bonne G, et al. Zidovudine myopathy: a distinctive disorder associated with mitochondrial dysfunction. Ann Neurol 1991; 29:606-614.
64. Casademont J, Barrientos A, Grau JM, et al. The effect of zidovudine on skeletal muscle mtDNA in HIV-1 infected patients with mild or no muscle dysfunction. Brain 1996; 119:1357-1364.
65. Jaffe JA, Kimmel PL. Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 2006; 1:655-667.
66. Knochel JP, Barcenas C, Cotton JR, et al. Hypophosphatemia and rhabdomyolysis. J Clin Invest 1978; 62:1240-1246.
67. Knochel J, Schlein E. On the mechanism of rhabdomyolysis in potassium depletion. J Clin Invest 1972; 51:1750-1758.
68. Chuck SK, Penzak SR. Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidemia. Expert Opin Drug Saf 2002; 1:5-17.
69. Fontaine C, Guaird-Schmid JB, Slama L, et al. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate. AIDS 2005; 19:1927-1928.
70. Moro H, Tsukada H, Tanuma A, et al. Rhabdomyolysis after simvastatin therapy in an HIV-infected patient with chronic renal failure. AIDS Patient Care STDS 2004; 18:687-690.
71. Mah Ming JB, Gill MJ. Drug-induced rhabdomyolysis after concomitant use of clarithromycin, atorvastatin, and lopinavir/ritonavir in a patient with HIV. AIDS Patient Care STDS 2003; 17:207-210.
72. Hare CB, Vu MP, Grunfeld C, Lampiris HW. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis 2002; 35:e111-e112.
73. Aboulafia DM, Johnston R. Simvastatin-induoed rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS 2000; 14:13-18.
74. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm 2002; 59:728-730.
75. Castro JG, Gutierrez L. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am J Med 2002; 112:505.
76. Boccia RV, Gelmann EP, Baker CC, et al. A hemolytic-uremic syndrome with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 101:716-717.
77. Ruggenenti P, Norris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001; 60:831-846.
78. Alpers CE. Light at the end of the TUNEL: HIV-associated thrombotic microangiopathy. Kidney Int 2003; 63:385-396.
79. Kimmel PL. The nephropathies of HIV infection: pathogenesis and treatment. Current Opinion Nephrol Hyper 2000; 9:117-122.
80. Becker S, Fusco G, Fusco J, et al. HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study. Clin Infect Dis 2004; 39:5267-3275.
81. Moore RD. Schistocytosis and a thrombotic microangiopathy-like syndrome in hospitalized HIV-infected patients. Am J Hematol 1999; 60:116-120.
82. Gervasoni C, Ridolfo AL, Vaccarezza M, et al, Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy. Clin Infect Dis 2002; 35:1534-1540.
83. Gunther K, Garizio D, Nesara P. ADAMTS13 activity and the presence of acquired inhibitors in human immunodeficiency virus-related thrombotic thrombocytopenic purpura. Transfusion 2007; 47:1710-1716. A critical study that gives insight into the underlying pathophysiology of HIV-associated TTP.
84. Gadallah MF, el-Shahawy MA, Campese VM, et al. Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. Am J Nephrol 1996; 16:446-450.
85. Kwaan HC, Bennett CL Thrombotic thrombocytopenic purpura 2005. Sem Thrombos Hemos 2005; 31:611-624.
86. Zimrin AB, Hess JR. Thrombotic thrombocytopenic purpura: going with the evidence. Crit Care Med 2006; 34:2247-2248.
87. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. HIV-associated immune-mediated renal disease. Kidney Int 1993; 44:1327-1340.
88. Stokes MB, Chawla H, Brody RI, et al. Immune complex glomerulonephritis in patients co-infected with HIV and hepatitis C virus. Am J Kidney Dis 1997; 29:514-525.
89. Kimmel PL, Phillips TM, Ferreira-Centeno A, et al. Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection. N Engl J Med 1992; 327:729-730.
90. Haas M, Kaul S, Eustace JA. HIV-associated immune complex glomerulonephritis with 'lupus-like' features: a clinicopathologic study of 14 cases. Kidney Int 2005; 67:1381-1390.
91. Nochy D, Glotz D, Dosquet P, et al. Renal disease associated with HIV infection: a multicentric study of 60 patients from Paris hospitals. Nephrol Dial Transplant 1993; 8:11-19.
92. Schectman JM, Kimmel PL. Remission of hepatitis-B associated membranous glomerulonephritis in human immunodeficiency virus infection. Am J Kidney Dis 1991; 17:716-718.
93. Kimmel PL, Abraham AA, Phillips TM. Membranoproliferative glomerulonephritis in a patient treated with interferon-alpha for human immunodeficiency virus infection. Am J Kidney Dis 1994; 24:858-863.
94. di Belgiojoso GB, Genderini A, Bertoli S, et al. Immunotactoid glomerulopathy in a HIV-infected patient: a novel association. Nephrol Dial Transplant 1996; 11:857-859.
95. Haas M, Rajaraman S, Ahuja T, et al. Fibrillary/immunotactoid glomerulonephritis in HIV-positive patients: a report of three cases. Nephrol Dial Transplant 2000; 15:1679-1683.
96. Markowitz GS, Cheng J-T, Colvin RB, et al. Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy. J Am Soc Nephrol 1998; 9:2244-2252.
97. Szczech LA, Gupta SK, Habash R, et al. The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney Int 2004; 66:1145-1152.
98. Chan-Tack KM, Ahuja N, Weinman EJ, et al. Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient. Am J Med Sci 2006; 332:364-367.
99. Cohen SD, Kimmel PL. Immune complex renal disease and human immunodeficiency virus infection. Semin Nephrol (in press). A critical review of immune complex glomerulonephritis in the setting of HIV infection.